These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26806502)

  • 1. [PATHWAY-2 Study: spironolactone vs placebo, bisoprolol and doxazosin to determine optimal treatment of resistant hypertension. Spironolactone high effective in lowering blood pressure in drug resistant hypertension].
    Widimský J
    Vnitr Lek; 2015 Dec; 61(12):1067-71. PubMed ID: 26806502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
    Williams B; MacDonald TM; Morant S; Webb DJ; Sever P; McInnes G; Ford I; Cruickshank JK; Caulfield MJ; Salsbury J; Mackenzie I; Padmanabhan S; Brown MJ;
    Lancet; 2015 Nov; 386(10008):2059-2068. PubMed ID: 26414968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.
    Williams B; MacDonald TM; Morant SV; Webb DJ; Sever P; McInnes GT; Ford I; Cruickshank JK; Caulfield MJ; Padmanabhan S; Mackenzie IS; Salsbury J; Brown MJ;
    Lancet Diabetes Endocrinol; 2018 Jun; 6(6):464-475. PubMed ID: 29655877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in understanding and managing resistant/refractory hypertension.
    Doumas M; Imprialos KP; Kallistratos MS; Manolis AJ
    F1000Res; 2020; 9():. PubMed ID: 32201574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spironolactone and doxazosin treatment in patients with resistant hypertension.
    Rodilla E; Costa JA; Pérez-Lahiguera F; Baldó E; González C; Pascual JM
    Rev Esp Cardiol; 2009 Feb; 62(2):158-66. PubMed ID: 19232189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PURLs: Resistant hypertension? Time to consider this fourth-line drug.
    Kaysin A; Mounsey A
    J Fam Pract; 2016 Apr; 65(4):266-8. PubMed ID: 27262250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACP Journal Club. In resistant hypertension, add-on spironolactone reduced SBP more than placebo, doxazosin, or bisoprolol over 12 wk.
    Rosenberg M; Stephens E
    Ann Intern Med; 2016 Feb; 164(4):JC16. PubMed ID: 26882301
    [No Abstract]   [Full Text] [Related]  

  • 8. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.
    Václavík J; Sedlák R; Plachy M; Navrátil K; Plásek J; Jarkovsky J; Václavík T; Husár R; Kociánová E; Táborsky M
    Hypertension; 2011 Jun; 57(6):1069-75. PubMed ID: 21536989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Spironolactone versus placebo, bisoprolol and doxazosin to determine the optimal treatment for drug-resistant hypertension].
    Divisón Garrote JA; Escobar Cervantes C
    Semergen; 2016 Oct; 42(7):e108-e109. PubMed ID: 26948046
    [No Abstract]   [Full Text] [Related]  

  • 10. PATHWAY-2: spironolactone for resistant hypertension.
    Dale A; Hartley P; Goldacre B;
    Lancet; 2016 Apr; 387(10026):1372-1373. PubMed ID: 27115813
    [No Abstract]   [Full Text] [Related]  

  • 11. PATHWAY-2: spironolactone for resistant hypertension.
    Gkaliagkousi E; Gavriilaki E; Triantafyllou A; Douma S
    Lancet; 2016 Apr; 387(10026):1372. PubMed ID: 27115812
    [No Abstract]   [Full Text] [Related]  

  • 12. PATHWAY-2: spironolactone for resistant hypertension.
    Boutari C; Stavropoulos K; Imprialos K; Doumas M; Karagiannis A
    Lancet; 2016 Apr; 387(10026):1371-1372. PubMed ID: 27115810
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypertension: PATHWAY to improving the treatment of drug-resistant hypertension.
    Huynh K
    Nat Rev Nephrol; 2015 Nov; 11(11):629. PubMed ID: 26434401
    [No Abstract]   [Full Text] [Related]  

  • 14. Spironolactone for resistant hypertension--hard to resist?
    Sternlicht H; Bakris GL
    Lancet; 2015 Nov; 386(10008):2032-2034. PubMed ID: 26414969
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension.
    Vaclavik J; Sedlak R; Jarkovsky J; Kocianova E; Taborsky M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Mar; 157(1):50-5. PubMed ID: 23128822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PATHWAY-2: spironolactone for resistant hypertension - Authors' reply.
    Williams B; MacDonald TM; Morant SV; Brown MJ
    Lancet; 2016 Apr; 387(10026):1373-1374. PubMed ID: 27115814
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension.
    Williams B; MacDonald TM; Caulfield M; Cruickshank JK; McInnes G; Sever P; Webb DJ; Salsbury J; Morant S; Ford I; Brown MJ
    BMJ Open; 2015 Aug; 5(8):e008951. PubMed ID: 26253568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Systematic Review of Add-on Pharmacologic Therapy in the Treatment of Resistant Hypertension.
    Tataru AP; Barry AR
    Am J Cardiovasc Drugs; 2017 Aug; 17(4):311-318. PubMed ID: 28349274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Benefits of spironolactone as the optimal treatment for drug resistant hypertension. Pathway-2 trial review].
    Prado JC; Ruilope LM; Segura J
    Hipertens Riesgo Vasc; 2016; 33(4):150-154. PubMed ID: 27363610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial.
    Oliveras A; Armario P; Clarà A; Sans-Atxer L; Vázquez S; Pascual J; De la Sierra A
    J Hypertens; 2016 Sep; 34(9):1863-71. PubMed ID: 27327441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.